Docket No.: 9551-022 NATL

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION: Harvey POLLARD et al.

GROUP ART UNIT:

SERIAL NUMBER:

10/560,590 EXAMINER:

FILED: December 13, 2005

AMPHIPHILIC PYRIDINIUM COMPOUNDS, METHOD OF MAKING AND USE THEREOF EOD.

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97

Commissioner for Patents PO BOX 1450

ALEXANDRIA, VA 22313-1450

Sir

Applicant(s) wish(es) to disclose the following information.

### REFERENCES

- Applicant(s) wish(es) to make of record the documents listed on the attached Form PTO-1449. Copies of the listed documents are attached, where required, as are either statements of relevancy or any readily available full or partial English translations of any non-English-language documents. The listing of a document on the attached form attached PTO-1449 should not be taken as an admission that such documents are prior art.
- Applicant(s) wish(es) to make of record the documents listed on the attached International Search Report and Form PTO/SB/08a. Copies of the listed documents are attached, where required, as are either statements of relevancy or any readily available full or partial English translations of any non-English-language documents. The listing of a document on the attached International Search Report and Form PTO/SB/08a should not be taken as an admission that such documents are prior art.

### RELATED CASES

Attached is a list of Applicant's(s') pending applications and issued patents which may be related to the present application. Copies of the documents, where required, are attached along with Form PTO-1449.

### CERTIFICATION

### The undersigned certifies that

- each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application for the first time (to the knowledge of the undersigned, having made reasonable inquiry) not more than three months prior to the filing of this
- no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement.

### BASIS FOR CONSIDERATION

This Information Disclosure Statement is filed:

- without fee and within three months of the filing date of the application.
- without fee and within three months of the date of entry of the U.S. national stage.
- without fee and before the mailing date of a first Office Action on the merits (to the knowledge of the undersigned).
- without fee and with the appropriate certification above.
- without fee and with a new CPA application.
  - without fee and with a Request for Continued Examination.
- with fee and before the mailing date of any Final Office Action, Notice of Allowance or an action that otherwise closes prosecution (to the knowledge of the undersigned).
- with fee, appropriate certification above, and before payment of the Issue Fee.

# DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 50-1442.

1200 Nineteenth Street, N.W. Washington, DC 20036-2412 Telephone No. (202) 861-3900 Facsimile No. (202) 223-2085

Respectfully submitted, DLA PIPER US LLP

Ping Wang Registration No.: 48,328